Moy RH, Fernandes GDS, Jonsson P, et al. - Researchers investigated the impact of regorafenib on the antitumor effect of first-line chemotherapy in metastatic esophagogastric cancer via performing a single-center phase 2 study. Overall, 36 patients with prior untreated metastatic gastroesophageal adenocarcinoma were administered 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) every 14 days and regorafenib 160 mg daily on days 4 to 10 of each 14-day cycle. They noted good tolerability of regorafenib (one week on–one week off schedule) combined with first-line FOLFOX; however, this treatment regimen did not offer an improved 6-month progression-free survival vs the historical control.